Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 19/20 | 0.79 |
| ▸ | THRB | P10828 | 19/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.79 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23245036 | 0.94 | THRA (0.88) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL25673785 | 0.89 | THRA (0.79) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| Resmetirom SCHEMBL2927241 | 0.89 | THRA (1.00) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL24548722 | 0.88 | THRA (0.67) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23245123 | 0.88 | THRA (0.78) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL30864240 | 0.88 | THRA (0.78) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL22632647 | 0.86 | THRA (0.91) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23022537 | 0.84 | THRA (0.88) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL23287540 | 0.84 | THRB (0.88) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| Resmetirom SCHEMBL22551615 | 0.84 | THRA (0.84) | THRATHRBCYP2C9CYP2C8UGT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | InventisBio Co., Ltd. (CN) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355110-A1 | THYROID HORMONE RECEPTOR AGONISTS | TSHR, THRA, TRHR | THRA 2/4885THRB 4/4885CYP2C9 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.